Salix Pharmaceuticals LTD (SLXP) financial statements (2021 and earlier)

Company profile

Business Address 8510 COLONNADE CENTER DRIVE
RALEIGH, NC 27615
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4991,158751
Cash and cash equivalents4991,158751
Receivables43134268
Inventory, net of allowances, customer advances and progress billings17510491
Inventory17510491
Prepaid expense and other current assets22
Other undisclosed current assets28988757
Total current assets:1,0062,2831,189
Noncurrent Assets
Property, plant and equipment352728
Long-term investments and receivables151515
Long-term investments151515
Intangible assets, net (including goodwill)2,982578622
Goodwill1,349181181
Intangible assets, net (excluding goodwill)1,633398442
Restricted cash and investments 750 
Other noncurrent assets9438
Prepaid expense and other noncurrent assets36
Other undisclosed noncurrent assets(15)(765)(15)
Total noncurrent assets:3,111643686
TOTAL ASSETS:4,1172,9261,875
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities225164121
Accounts payable463331
Accrued liabilities1799781
Taxes payable 359
Debt92100
Other undisclosed current liabilities329253140
Total current liabilities:1,475417261
Noncurrent Liabilities
Long-term debt and lease obligation 1,632857
Long-term debt, excluding current maturities 1,632857
Liabilities, other than long-term debt3005285
Deferred tax liabilities, net2854264
Other liabilities151021
Total noncurrent liabilities:3001,684942
Total liabilities:1,7752,1011,203
Stockholders' equity
Stockholders' equity attributable to parent238729561
Common stock000
Additional paid in capital595667631
Accumulated other comprehensive income (loss)(1)20
Retained earnings (accumulated deficit)(355)59(71)
Total stockholders' equity:238729561
Other undisclosed liabilities and equity2,10496111
TOTAL LIABILITIES AND EQUITY:4,1172,9261,875

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenues1,134914735
Cost of revenue(414)(178)(136)
Cost of goods and services sold(338)(178)(125)
Gross profit:720736599
Operating expenses(1,210)(500)(427)
Other undisclosed operating income 16 
Operating income (loss):(490)252172
Nonoperating expense
(Other Nonoperating expense)
(3)  
Interest and debt expense(171)(62)(71)
Other undisclosed income from continuing operations before equity method investments, income taxes 211
Income (loss) from continuing operations before income taxes:(664)192112
Income tax expense (benefit)249(61)(48)
Net income (loss) available to common stockholders, diluted:(415)13164

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net income (loss):(415)13164
Comprehensive income (loss):(415)13164
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)11
Comprehensive income (loss), net of tax, attributable to parent:(418)13265

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: